Company Overview
Syndax Pharmaceuticals, Inc. operates as a commercial-stage biopharmaceutical company dedicated to developing therapies specifically designed for the treatment of cancer. The company functions within the healthcare sector, specifically inside the biotechnology industry, a domain characterized by high research and development costs and reliance on innovative drug candidates to generate future revenue. As of the latest available data, the company maintains a market capitalization of $2.14B and employs a workforce of 298 individuals. While the annual revenue stands at $172.35M, the market cap significantly exceeds this revenue figure, indicating that the market values the company primarily on the potential of its pipeline assets, Revuforj and Niktimvo, rather than current cash flows. This valuation structure is typical for biotechnology firms where the primary asset is the intellectual property and clinical trial success of lead products rather than established profitable operations.
Financial Health
The company reported a revenue of $172.35M for the trailing twelve months, yet the net income was -$285,422,016, revealing a cost structure where expenses substantially outpace top-line generation. The EBITDA for the same period was -$273,478,016, further highlighting that even before interest and taxes, the operational costs are heavy relative to current sales. Free cash flow stands at -$210,053,120, which signifies that the company is currently burning cash and lacks the immediate financial flexibility to fund operations entirely from internal cash generation without external financing. The gross margin is listed at -54.2%, an unusual metric for a mature product but indicative of a pre-commercial or early commercial phase where cost of goods sold may exceed revenue due to specialized manufacturing or clinical trial overhead allocation. Operating margins are even more negative at -91.6%, and profit margins are at -165.6%, both figures confirming that the company is not yet profitable and is operating at a significant loss on every dollar of revenue. On the balance sheet, the company holds $413.69M in cash against $345.43M in debt, resulting in a debt-to-equity ratio of 534.48, which suggests a highly leveraged position relative to equity but provides a substantial cash buffer. The current ratio is 4.40, indicating strong short-term liquidity as the company possesses more than four times the current assets required to cover its current liabilities. Return on Equity is -161.8% and Return on Assets is -27.3%, metrics that reveal that management has not yet generated positive returns on the capital invested, reflecting the inherent risks and long development timelines typical of the biotechnology sector.
Valuation Assessment
The P/E Ratio (TTM) is N/A due to the lack of earnings, while the forward P/E is -153.21, a negative figure that implies expected earnings are currently negative and traditional price-to-earnings metrics are not applicable for valuation. The price-to-book ratio is 32.79, which indicates that the market is pricing the company at a massive premium over its book value, suggesting high expectations for the successful commercialization of its drug candidates. The price-to-sales ratio is 12.40, and the EV/EBITDA is -7.57, alternative metrics that suggest the market is valuing the company based on its sales volume and potential rather than current profitability. The stock has a 52-Week High of $25.44 and a 52-Week Low of $8.58, and without the current price explicitly stated in the provided facts, the valuation is anchored by this historical trading range which defines the recent volatility. The beta is 0.46, meaning the stock exhibits lower price volatility relative to the broader market, moving less than half as much as the market index during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is reported at an extraordinary 794.9%, while earnings growth is N/A due to the company's consistent losses, indicating that top-line expansion is occurring without corresponding profit improvement. Because the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, reflecting a strategy of reinvesting all available resources into research and development rather than distributing income to shareholders. The absence of a dividend payout ratio of 0.0% confirms that the company prioritizes capital allocation toward growth initiatives and clinical trials over returning cash to investors. Overall, the growth and income profile is defined by rapid revenue expansion coupled with significant cash burn, a dynamic common in late-stage biotechnology companies awaiting regulatory approval and commercial launch of their therapeutic candidates.